Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25048303 | 1.00 | HTR2A (0.32) | HTR2AHTR2CHTR2BGAAMAPK1 | |
| SCHEMBL30941554 | 0.92 | METTL3 (0.35) | HTR2AHTR2CHTR2BGAAMAPK1 | |
| SCHEMBL30941728 | 0.92 | METTL3 (0.35) | HTR2AHTR2CHTR2BGAAMAPK1 | |
| SCHEMBL25047760 | 0.92 | METTL3 (0.35) | HTR2AHTR2CHTR2BGAAMAPK1 | |
| SCHEMBL25048451 | 0.91 | — | — | |
| SCHEMBL25046763 | 0.83 | HTR2A (0.34) | HTR2AHTR2CHTR2BGAAMAPK1 | |
| SCHEMBL25048847 | 0.83 | METTL3 (0.34) | METTL3 | |
| SCHEMBL31618085 | 0.83 | METTL3 (0.33) | METTL3 | |
| SCHEMBL25048356 | 0.83 | METTL3 (0.33) | METTL3 | |
| SCHEMBL30941203 | 0.83 | METTL3 (0.33) | METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | HTR2A 4683/4885HTR2C 4689/4885HTR2B 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.